Company / Operating Income
Vertex Pharmaceuticals Operating Income History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
$4.2B
FY2025
5-year range
-$232.9M / $4.3B
FY2021-FY2025
Trend
+1891.9%
vs FY2024
Sector context
#5 of 204
Health Care
What the data says
Operating Income changed +1892% YoY in FY2025, a notable deviation from the 9-year average annual change of +401%.
Based on SEC 10-K filings.
$4.2B in FY2025 with a 5-year CAGR of +7.9%. Top quartile in the Health Care sector.
Improved from $3.8B to $4.2B over the past 2 years.
Health Care sector context is included.
Operating Income over time
Growth rates
- 3-Year CAGR
- -1.0%
- 5-Year CAGR
- +7.9%
- 10-Year CAGR
- -
Sector benchmark
Top 2% in Health CareTop 2% of 204This company $4.2B Sector average $107.7M
▼
+3774.3% above sector average
Key checks
Key Insights
- 5-year CAGR of +7.9%, indicating consistent growth.
- In FY2025, operating income increased 1891.9% year-over-year.
- Ranks #5 out of 204 companies in the Health Care sector.
- Peak operating income was recorded in FY2022.
Company context
Key Data Points
- Strong profit margin: 31.4%
- Strong return on equity: 21.2%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $4.2B | +1891.9% |
| FY2024 | -$232.9M | -106.1% |
| FY2023 | $3.8B | -11.0% |
| FY2022 | $4.3B | +54.8% |
| FY2021 | $2.8B | -2.6% |
| FY2020 | $2.9B | +138.5% |
| FY2019 | $1.2B | +88.5% |
| FY2018 | $635.1M | +415.4% |
| FY2017 | $123.2M | +1140.4% |
| FY2016 | $9.9M | +102.1% |
As of FY2025 · SEC 10-K · Updated Mar 17, 2026